Assembly Biosciences Chief Manufacturing Officer Nicole S. White filed a Form 4 on November 3, 2026, disclosing a performance-based restricted stock unit award settlement and mandatory sell-to-cover share sales on October 30 and November 2, 2026.

Key Highlights

  • RSU award settlement: Nicole S. White acquired 13,705 shares of common stock on October 30, 2026, at $0, upon achievement of a performance-based vesting condition under an award dated June 16, 2025.
  • Mandatory sell-to-cover: 2,564 shares were sold on November 2, 2026, at a weighted average price of $19.6077, in multiple transactions ranging from $19.28 to $20.27 per share.
  • Second sell-to-cover tranche: An additional 29 shares were sold on November 2, 2026, at a weighted average price of $20.348, in transactions ranging from $20.30 to $20.37 per share.
  • Resulting ownership: Following all reported transactions, White directly beneficially owned 59,257 shares of common stock.
  • Remaining vest: The award vests in two equal installments; the second installment is scheduled for October 30, 2027, subject to continuous service.
  • Sell-to-cover basis: According to the filing, the sales were mandated by an administrative rule adopted by the Compensation Committee requiring tax withholding obligations to be satisfied through a sell-to-cover transaction and "do not represent discretionary transactions by the reporting person."

Performance RSU Vesting and Tax-Related Sales by Assembly Biosciences CMO

According to the Form 4 filed with the SEC, Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, Inc. (NASDAQ:ASMB), reported that on October 30, 2026, the performance-based vesting condition under a restricted stock unit award dated June 16, 2025, was achieved. This triggered the acquisition of 13,705 shares of common stock at a price of $0, bringing her directly held beneficial ownership to 61,850 shares at that point.

The filing disclosed that on November 2, 2026, White sold a total of 2,593 shares across two separate transactions, both classified as sell-to-cover sales. The first transaction involved 2,564 shares sold at a weighted average price of $19.6077, with individual sale prices ranging from $19.28 to $20.27 per share. The second transaction covered 29 shares sold at a weighted average price of $20.348, with prices ranging from $20.30 to $20.37 per share. The filing stated that these sales were mandated by a Compensation Committee administrative rule requiring tax withholding obligations connected with RSU vesting and settlement to be funded through a sell-to-cover arrangement.

After all reported transactions, White's direct beneficial ownership stood at 59,257 shares of Assembly Biosciences common stock, according to the filing. The award structure provides for vesting in two equal installments, with the first installment having vested on October 30, 2026, and the second scheduled for October 30, 2027, subject to continuous service on each vesting date. The Form 4 was signed by John O. Gunderson as Attorney-in-Fact and filed on November 3, 2026.

What Was Disclosed

The filing reported the settlement of a performance-based RSU award granting 13,705 shares to Chief Manufacturing Officer Nicole S. White, along with two mandatory sell-to-cover share sales totaling 2,593 shares to satisfy tax withholding obligations, resulting in direct ownership of 59,257 shares.